A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer (PFE) is running a Phase 2 study titled “AN ...

Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth ...

Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

Hympavzi was approved by the U.S. Food and Drug Administration (FDA) in October 2024 for routine prophylaxis in adults and ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...

FILE- A Pfizer logo is shown at their global supply Kalamazoo manufacturing plant in Portage, Mich., on Dec. 11, 2020. Pfizer’s updated COVID-19 booster significantly revved up adults’ virus-fighting ...

An experimental Pfizer hemophilia drug that takes a new approach to treating the blood clotting disorder has met the main goal of a pivotal study, setting the stage for regulatory submissions planned ...

Pfizer’s updated COVID-19 booster significantly revved up adults’ virus-fighting antibodies, the company said Friday, releasing early findings from a rigorous study of the new shots. Booster doses ...

Pfizer’s updated COVID-19 booster significantly revved up adults’ virus-fighting antibodies, the company said Friday, releasing early findings from a rigorous study of the new shots. Booster doses ...